Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
12/2003
12/16/2003US6664229 Methods for treatment using novel ligands of the neuropeptide receptor HFGAN72
12/16/2003CA2246289C New associations of active principles containing clopidogrel and an antithrombotic agent
12/16/2003CA2124578C A mixture of higher primary aliphatic alcohols, its obtention from sugar cane wax and its pharmaceutical uses
12/16/2003CA2096604C Protein c derivatives
12/11/2003WO2003102180A1 NOVEL PEPTIDES HAVING cAMP PRODUCING ACTIVITY
12/11/2003WO2003102151A2 Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors
12/11/2003WO2003102138A2 Elongase genes and uses thereof
12/11/2003WO2003101981A1 Novel substituted indoles
12/11/2003WO2003101980A1 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors
12/11/2003WO2003101957A1 New salts
12/11/2003WO2003101956A1 Pharmaceutical combination
12/11/2003WO2003101490A1 Drug composition containing calcium channel antagonist
12/11/2003WO2003101485A1 Cd16a binding proteins and use for the treatment of immune disorders
12/11/2003WO2003101457A1 Peritoneal dialysis solution with taurolidine
12/11/2003WO2003101450A1 N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris
12/11/2003WO2003101424A1 Modified release pharmaceutical formulation
12/11/2003WO2003101423A1 Immediate release pharmaceutical formulation
12/11/2003WO2003101374A2 Use of new etonogestrel esters
12/11/2003WO2003101281A2 Method for reducing obstructive hydrocephalus
12/11/2003WO2003101177A2 Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
12/11/2003WO2003080630A3 Phosphate transport inhibitors
12/11/2003WO2003057666A3 Inhibitors of dipeptidyl peptidase iv
12/11/2003WO2003051180A3 METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS USING 252, 304, 19870, 14717, 9941, 19310 and 17832
12/11/2003WO2003026579A3 Combination therapies for immune mediated diseases
12/11/2003WO2003022216A3 Biaryl substituted purine derivatives as potent antiproliferative agents
12/11/2003WO2003003975A3 Detection and therapy of vulnerable plaque with photodynamic compounds
12/11/2003WO2003000179A3 Chemically-modified progenipoietin conjugates
12/11/2003WO2002087508A3 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
12/11/2003WO2002085925A3 Melanocortin receptor ligands
12/11/2003WO2002083841A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/11/2003WO2002062778A3 Anti-thrombotic compounds, production and use thereof as medicaments
12/11/2003US20030229231 Forming chelate compounds
12/11/2003US20030229204 PCG-1, a novel brown fat PPARgamma coactivator
12/11/2003US20030229133 Amidine inhibitors of serine proteases
12/11/2003US20030229110 Cell signal transduction
12/11/2003US20030229092 Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens
12/11/2003US20030229080 Cardiovascular disorders; sexual disorders
12/11/2003US20030229047 Liquid formulation of decitabine and use of the same
12/11/2003US20030229012 Administering transferrin for blood disorders
12/11/2003US20030228625 Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome
12/11/2003US20030228371 Anti-infarction molecules
12/11/2003US20030228365 Pharmaceutical formulation
12/11/2003US20030228282 Genetic engineered polypeptide; inserted into cell; blood disorders
12/11/2003CA2488238A1 Method for reducing obstructive hydrocephalus
12/11/2003CA2488013A1 Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
12/11/2003CA2487932A1 Cd16a binding proteins and use for the treatment of immune disorders
12/11/2003CA2487509A1 New salts
12/11/2003CA2487293A1 Use of new etonogestrel esters
12/11/2003CA2486110A1 Pharmaceutical combination
12/11/2003CA2485533A1 Immediate release pharmaceutical formulation
12/10/2003EP1369432A2 Soluble highly branched glucose polymers and process for their preparation
12/10/2003EP1369421A1 Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives
12/10/2003EP1369420A1 Inhibitors of the GPib - vWF interaction
12/10/2003EP1369128A1 Inhibitors of glycoprotein VI and their therapeutic use
12/10/2003EP1369123A1 A health-care product comprising lotus rhizome and process for its preparation
12/10/2003EP1368473A2 Neurotransmission-associated proteins
12/10/2003EP1368419A2 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
12/10/2003EP1368364A1 C2, 8-disubstituted adenosine derivatives and their different uses
12/10/2003EP1368341A1 Phenyl derivatives 3
12/10/2003EP1368335A2 Novel amino dicarboxylic acid derivatives with pharmaceutical properties
12/10/2003EP1368314A1 N-4-piperidinyl compounds as ccr5 modulators
12/10/2003EP1368304A1 Prodrugs of excitatory amino acids
12/10/2003EP1368302A1 Novel amino dicarboxylic acid derivatives
12/10/2003EP1368301A1 Side-chain halogenated amino carboxylic acid derivatives as medicaments for treating cardiovascular diseases
12/10/2003EP1368300A1 Substituted amino dicarboxylic acid derivatives
12/10/2003EP1368056A1 Recombinant gelatin-like proteins for use as plasma expanders
12/10/2003EP1368025A2 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
12/10/2003EP1367899A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
12/10/2003EP1289985B1 Beta-carboline derivatives useful as inhibitors of phosphodiesterase
12/10/2003EP1189916B1 N-pyrazole a 2a receptor agonists
12/10/2003EP1163243B1 Calanolides for inhibiting btk
12/10/2003EP0771146B1 Fibrin(ogen) degradation and clot lysis by fibrinolytic matrix metalloproteinase
12/10/2003EP0671924B1 Digitalis-like compounds
12/10/2003EP0502892B1 THE HUMAN C3b/C4b RECEPTOR (CR1)
12/10/2003CN1461310A ANtibodies that bind human interleukin-18 and methods of making and using
12/10/2003CN1461215A A personal condition management system
12/10/2003CN1460511A Prpearation method of xueshuan xinmoining Chinese medicine for curing cerebrovascular diseases
12/10/2003CN1460510A Chinese patent medicine with the functions of replenishing qi and blood and nourishing the heart to calm the mind, its preparation method and quality control method
12/10/2003CN1460509A Chinese patent medicine for curing cardiovascular disease, its preparation method and quality control method
12/10/2003CN1460487A Propolis soft capsule and its preparation method
12/10/2003CN1460482A Medicine composite containing icaritin and demethylicaritin and its application
12/10/2003CN1460469A Preparation method of aspirin microsphere
12/10/2003CN1130347C 2,3-methylene amino acid compounds, their preparing method and pharmaceutical composition containing them
12/10/2003CN1130214C Medicine for treating purpura caused by lupus erythematosus and other immunological disease
12/10/2003CN1130205C Biochemically balanced peritoneal dialysis solutions
12/09/2003US6660839 Tumor necrosis related receptor, TR7
12/09/2003US6660746 Cardiovascular disorders
12/09/2003US6660744 Pyrazolopyrimidines as therapeutic agents
12/09/2003US6660739 Heterocyclic amides as inhibitors of factor Xa
12/09/2003US6660738 Such as (3R,5S)-1-pyrimidin-2-yl-5-(2,4,5-trifluoro-benzyloxymethyl)-pyrrolidine-3 -thiol trifluoro-acetate useful as inhibitors of metalloproteases for treating diseases associated with vasoconstriction
12/09/2003US6660732 Ureas and thioureas inhibit production of cytokines
12/09/2003US6660724 Compounds and pharmaceutical compositions containing them
12/09/2003US6660257 Flt-3 receptor agonist proteins; nucleic acid sequence
12/09/2003US6660247 Multiple stimulus reversible hydrogels
12/09/2003CA2266318C Flavonol containing food supplements
12/09/2003CA2078758C 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
12/09/2003CA1341449C Poly-kringle plasminogen activator
12/04/2003WO2003100435A2 Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
12/04/2003WO2003100087A2 Regulation of novel human asparagine-hydroxylases
12/04/2003WO2003099820A1 Pyrazolo-pyrimidine aniline compounds
1 ... 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 ... 671